Understanding these risk factors is essential for comprehensive patient management and appropriate risk stratification
A significant milestone for the industry Teva Pharmaceuticals entering the GLP-1 space with the first FDA-approved generic marks the beginning of a new chapter in obesity and diabetes care
Furthermore, in the large-scale SELECT clinical trial, Wegovy was shown to reduce the risk of major cardiovascular adverse events by up to 20% [data sourced from MIMS Hong Kong]
Tuy nhin, nu bn mun dng cht ny cho mt mc tiu c th, hy tham kho kin bc s c t vn v s dng ng cch bn nh.
This combination typically reduces HbA1c by 1020 mmol/mol with minimal hypoglycaemia risk compared to insulin-based regimens
Key Benefits Enhance GLP-1 receptor activation and sustain its response with a combination of clinically studied prebiotics, probiotics, postbiotics, and fast-acting GLP-1 activators that work synergistically Control appetite by reducing cravings and stimulating satiety signals with hops extract, probiotic, and postbiotic* Promote digestive health and regularity with a prebiotic that promotes the growth of Akkermansia muciniphila for GLP-1 signaling Free from gluten, dairy, peanut, tree nut, fish, shellfish, soy, sesame, egg, active yeast, artificial flavors, colors, sweeteners, and unnecessary excipients